TriSalus Life Sciences, Inc.
TLSI- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001826667
No open-market purchases or sales by TriSalus Life Sciences, Inc. insiders were filed in the last 90 days; 78 institutions reported holding it in 13F filings for Q2 2026, worth $103.5M in total; no superinvestor holds it.
Other share classesTLSIW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 78
- 13F valueReported value at the end of Q2 2026
- $103.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TLSI, Q2 2026
No superinvestor reported holding TLSI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by TriSalus Life Sciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 (view filing) | May 15 | 4 days | Marshak RichardChief Commercial Officer | SSale | −543 | $2.67 | −$1.45K | −0.4%125.1K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Wahlstrom MatsDirector | PPurchase | +60.0K | $2.53 | +$151.8K | +68.5%147.6K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +410.0K | $2.50 | +$1.02M | +49.4%1.24M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +200.0K | $2.50 | +$500.0K | +100.2%399.7K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Szela Mary TCEO and President | PPurchase | +39.7K | $2.59 | +$102.8K | +3.9%1.07M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Patience DavidChief Financial Officer | PPurchase | +7.10K | $2.43 | +$17.3K | +2.6%275.8K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Gordon Gary B.Director | PPurchase | +10.0K | $2.46 | +$24.6K | +16.0%72.5K after | |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Devlin JodiChief of Clinical Operations | SSale | −3.21K | $4.11 | −$13.2K | −3.2%97.4K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Cox Bryan F.Chief of Research | SSale | −3.18K | $4.11 | −$13.1K | −1.9%163.4K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Marshak RichardChief Commercial Officer | SSale | −3.46K | $4.11 | −$14.2K | −3.0%110.4K after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in TriSalus Life Sciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| First Light Asset Management, LLC | 6,552,491 | $29.8M | 1.81% | +1,485,664+29.3% | Added |
| BlackRock, Inc. | 2,659,218 | $12.1M | 0.00% | +1,159,671+77.3% | Added |
| Nantahala Capital Management, LLC | 2,000,000 | $9.10M | 0.28% | −70,827−3.4% | Reduced |
| Vanguard Capital Management LLC | 1,729,385 | $7.87M | 0.00% | +382,349+28.4% | Added |
| Cerity Partners LLC | 1,603,538 | $7.30M | 0.01% | +816,266+103.7% | Added |
| Geode Capital Management, LLC | 1,190,067 | $5.42M | 0.00% | +412,973+53.1% | Added |
| Gilder Gagnon Howe & Co LLC | 850,081 | $3.87M | 0.04% | −38,434−4.3% | Reduced |
| State Street Corp | 610,963 | $2.78M | 0.00% | +282,943+86.3% | Added |
| White Pine Capital LLC | 547,577 | $2.49M | 0.59% | +183,922+50.6% | Added |
| Thompson Siegel & Walmsley LLC | 536,534 | $2.44M | 0.04% | −47,040−8.1% | Reduced |